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Over the past three decades the pancreatic islet of
Langerhans has taken center stage as an endocrine microorgan whose glucoregulatory function is highly explicable
on the basis of the increasingly well understood activities
of three highly interactive secretory cells. Islet dysfunction
underlies both type 1 and type 2 diabetes mellitus (DM); its
protection from immune attack and gluco-and lipo-toxicity
may prevent the development of DM; and its replacement
by non-surgical transplantation may be curative of DM.
During a career marked by vision, focus and tenacity, Paul
Lacy contributed substantially to the development of
each of these concepts. In this review we focus on Lacy’s
contribution to the development of the concept of the
islet as a micro-organ, how this foreshadowed our current
detailed understanding of single cell function and cell-cell
interactions and how this led to a reduced model of islet
function encouraging islet transplantation. Next, we examine
how clinical allotransplantation, first undertaken by Lacy, has
contributed to a more complex view of the interaction of islet
endocrine cells with its circulation and neighboring tissues,
both “in situ” and after transplantation. Lastly, we consider
recent developments in some alternative approaches to
treatment of DM that Lacy could glimpse on the horizon but
did not have the chance to participate in.

Introduction
“I started my career wanting to learn about the structural basis and
cell mechanics of insulin secretion and ended it trying to cure diabetes with islet transplantation. Gosh, what a surprising turn a life in
science can take!” (Paul Lacy, September 1987).
Throughout his academic career at Washington University,
from the early 1950s, as a newly minted Assistant Professor of
Pathology, to the mid 1990s, when he retired as Kroc Professor of
Pathology after a prior long term as departmental chairman, the
late Paul Lacy had a focused, “islet-centric” scientific interest.1
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He wished to learn as much as he could about the function, especially insulin secretion, of the pancreatic islet of Langerhans. In
the first phase of that career (1955–1973), he studied the intricate
in situ ultrastructure and in vitro function of the islet. He made
a major contribution towards characterizing the substructure of
component a, b and d cells by techniques including selective
staining and secretagogue-induced granule depletion. He identified granule “emiocytosis” (exocytosis) as the key mechanism
of hormone exit from islet cells. In addition, he recognized the
importance of granule maturation and movement as well as Ca 2+
entry and the cytoskeleton in the exocytotic process. In doing
this he provided a first working model for biphasic insulin secretion. Moreover, his development of the isolated islet preparation
made possible detailed enzymology, electrophysiology and living
tissue microscopy.
In the second phase of his career (1973–1995), Lacy mounted
an all-out scientific mission. In a heroic bench-to-bedside effort
“to cure diabetes mellitus in man by human islet transplantation,” he developed and disseminated key techniques of human
islet purification from cadaver donors and subsequent portal
vein infusion into recipients. His specific aim was “to harvest
as many pancreatic islets of Langerhans as possible, keep them
healthy, make them non-antigenic, and then, by golly to transplant them into a safe space in the body,” where they’d “take up
root,” “appropriately secrete insulin after a meal” and “substitute
for the sick islets of the diabetic pancreas that couldn’t.” With
glucose-sensitive islets secreting insulin on a moment-to-moment
basis “the highs and lows of blood sugar and the end-organ damage of diabetes seen after years of diabetes would be prevented.”
This work culminated in the first trials of clinical trials of islet
transplantation in 1990. By articulating this goal with a magical
presence, a combination of a folksy Midwestern grandiloquence
and a twinkle in his eye that assured even the casual listener of
a self-evident truth, he raised awareness, hope and funding for
a simple and elegant approach at organ replacement. However,
privately, he remained keenly aware of the Achilles heel of this
endeavor, namely the need for immunosuppression, the uncertainty of tissue supply and quality, and the potentially unsustainable function of islets in a foreign environment. From the early
1990s until his retirement from active science at Washington
University in 1995 to pursue a love of archeology, Lacy with
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David Scharp, his long-term partner in the human islet transplantation adventure, concentrated on a variation on the original
islet transplantation vision, xenotransplanation of much more
readily available porcine islets after their encapsulation.
To celebrate the legacy of Paul Lacy’s imaginative, tenacious, generous and, to be sure, “gutsy” life in science, as well
as his seminal contributions to the revival of the pancreatic islet
from relative investigative obscurity, this review shall focus on
the influence of Lacy’s seminal techniques of islet isolation, his
exploration of islet function as well as his vision of curative islet
transplantation. Based on a critical review of the published work
of Lacy and his contemporaries and two in-depth conversations
I had with him in 1987 and 2000, I shall concentrate on several
features. First, how Lacy’s early work on islet function motivated
cellular and molecular studies of the past two decades that have
culminated in complex models of stimulus-secretion coupling in
individual islet cells and as well as produce a “reduced model of
islet function,” which formed the underlying assumptions of the
early vision of clinical islet transplantation. Second, how partial
realization of that vision promoted understanding of pancreatic
islets as unique micro-organs that maintain a complex internal
sociobiology, intricate developmental and functional ties with
their exocrine tissue neighbors, as well as important distant
interactions with immune surveillance cells, which may be critical to both autoimmunity of diabetes and islet transplant rejection. The latter provides an interesting study in how a simple
idea grows in complexity as it progresses from bench to bedside
and then back to bench.
Part I: The Islet as a Micro-Organ
Mass isolation of islets and its bonus to physiology, the unraveling of the details of stimulus-secretion coupling in b and a
cells. Research into the isolation of islets began in the 1960s
when tens of islets were liberated from rodent pancreas by enzymatic (collagenase) incubations of chopped tissue or free hand
microdissection of surface islets (reviewed in reference 2), both
usually from obese animals with hypertrophic islets. In a clear
technical breakthrough, in 1967 Lacy and Kostianovsky3 demonstrated the ability to harvest several hundred metabolically
active and structurally intact islets from the pancreas of a normal rat. Prior to digesting the fat-trimmed pancreas with collagenase, they distended and partially disrupted the enveloping
acini through retrograde injection of physiological saline into
the cannulated bile/pancreatic duct. The latter maneuver provided easier access of collagen to the interior of the pancreatic
tissue. Islets, which are dense ovoid bodies, were separated from
acini and ductal fragments by gravity sedimentation in a salinefilled cylinder or by centrifugation in a discontinuous sucrose
(or later Ficoll) gradient. Using this approach, up to several
hundred islets could be collected from a rodent pancreas, and
several thousand islets could be collected from the pancreas of
large mammal.
Success in harvesting islets and the subsequent ability to disperse these into a preparation of single cells, which could later
be separated into their component types, or into preparation of
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cytosolic components, especially insulin granules,4 could not
have come at a more propitious time. Insulin was being routinely and reliably measured by radioimmunoassay. In addition,
the rudiments of a general hypothesis for stimulus-secretion
coupling in b-cells were being established through several
approaches. Ashcroft and Randle in Oxford and Matschinsky
and group in St. Louis were providing strong evidence that glucose transport, phosphorylation and oxidation to CO2 + H2O
were essential for stimulation of insulin secretion and biosynthesis.5 Grodsky and colleagues,6,7 investigating secretion of insulin by the perfused pancreas into the hepatic vein, had already
shown that insulin release in response to a sustained rise in
glucose was biphasic and that both phases required aerobic oxidation of glucose and adequate concentrations of extracellular
Ca 2+. Dean and Matthews8 using microdissected islets, demonstrated that islet cells responded to a rise in ambient glucose by
depolarizing and then firing action potentials whose upstrokes
appeared to be dependent on the concentration of extracellular Ca 2+. As β-cell depolarization required glucose metabolism
and was associated with a decrease in membrane permeability to
K+, a link between b-cell metabolism and excitability was being
established. Hence, an outline of a hypothesis of stimulus-secretion coupling in β-cells was emerging: glucose metabolism, by
changing cell energetics was promoting electrical activity, which
in turn was promoting Ca 2+ entry and Ca 2+ -dependent exocytosis of insulin granules.
Work using all of these approaches was now made immensely
easier and more disseminatable by the technique for mass isolation of islets. Lacy’s lab, which had previously published a
host of electron microscopic images of maturation and “emiocytosis” (surface rupture and shower-like release of contents of
insulin granules in fixed tissue), demonstrated in monolayers of
cultured islets that granules, in constant motion, preferentially
approached the membrane after glucose stimulation; this was
inhibited after application of agents that disassemble cytoskeleton.9,10 On this basis Lacy proposed that biphasic insulin secretion seen with high glucose stimulation (>10 mM) might be
explained as follows. First phase insulin secretion, unaffected by
cytoskeletal disrupting agents, might result from the discharge
of granules already present (in contemporary terminology
“docked”) at the membrane. In contrast, second phase insulin
secretion, greatly decreased by cytoskeletal disrupting agents,
might result from granules moving towards the membrane along
cytoskeleton as their contents undergo progressive processing
and aggregation. In contemporary terminology this would be
while in transit from the Golgi to the plasma membrane, first by
kinesin motors along microtubules, then penetrating the cortical actin cage aided by myosin V motors, and lastly attaching to
the membrane via the formation of complexes between vesicle
(v-, VAMP) and target (t-, SNAP23/25, syntaxin) SNARE proteins. Later experiments demonstrated small oscillatory changes
in insulin secretion occurring near resting levels of glucose.10a
Within less than a decade of routine availability and dispersion
of isolated islets, powerful new techniques offered the prospect
of revolutionizing the entire field of stimulus-secretion coupling
in endocrine cells. These included: patch clamp recording of
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Figure 1. Proposed schemes of stimulus-secretion coupling in b- and a-cells of the islet. (A) Stimulus-secretion coupling in β-cells. Digestion of food in
the gut both increases blood glucose and releases incretins (acetylcholine and glucagon-like intestinal peptide), which trigger insulin secretion. GLP-1
via a G-protein coupled receptor stimulates the production of cAMP which serves to activate protein kinase A or Epac, while acetylcholine activates
via a G-protein coupled muscarinic receptor of CaM kinase II. (B) Stimulus-secretion coupling in a-cells. A rise in serum glucose and release of contents of insulin granule inhibits glucagon secretion. In contrast, hypoglycemia rapidly stimulates glucagon release by relieving glucose inhibition of
exocytosis, and by activating central nervous system stress pathways that turn release catecholamines (CA) from adrenergic nerve fibers and adrenal
medullary chromaffin cells. It is likely that CAs priming the docking of glucagon-containing granules into a readily-releasable pool.

single channel and whole cell currents underlying both the resting potential at basal levels of glucose and the complex electrical activity initiated by stimulatory glucose concentrations;11,12
optical monitoring of metabolic processes including mitochondrial membrane potential and free cytosolic ion concentration
with membrane permeant fluorescent probes;13 and cloning of
key transporter proteins including the ATP sensitive K channel.14 Ultimately they also included real time, single cell assays
of single cell exocytosis. Most prominent among these were the
following: (1) electrical measurements of increases in membrane
capacitance (Cm) proportional to plasma membrane surface area
in patch clamped cells, indicating increases in plasma membrane surface area due to fusion of organelles the size of insulin granules with the plasma membrane;15,16 (2) electrochemical
measurements, by oxidation or reduction of discharged of both
native hormone (insulin) and preloaded false transmitter (serotonin) contents17-19 of exocytosing granules, using carbon fiber
electrodes whose tips are positioned at the surface of cells, over
time courses very similar to the increases in Cm ; and (3) optical
tracking of granules with fluorescent labeled granule contents or
intramembrane proteins as they approach the plasma membrane
and fuse with it.
An overall consensus scheme for stimulus-secretion coupling in β-cells is presented in Figure 1A. A rise in serum
glucose from a baseline level of 3 mM to stimulatory levels of
5–6 mM enhances glucose import via a moderate affinity transporter
(glut-2) followed by shunting into glycolysis by glucokinase and
mitochondrial oxidation (step 1), results in a small rise in cytosolic
ATP and a fall in cytosolic ADP (step 2) sufficient to close down
ATP-dependent K-selective ion channels (step 3). The latter consist of an inner ring of four inward rectifier K channel subunits
(Kir 6.2), encompassing a pore closed by the binding of ATP,

and an outer ring of sulfonylurea receptors (SUR 2), interacting
with the central core in a fashion that binding of MgADP can
open, while binding of sulfonylureas can, close the Kir-defined
pore. The closure of K+(ATP) channels, against a background
of tonically open non-selective cation channels, constitutes the
basis for cell depolarization (step 4) and the activation of voltage
dependent Na+, Ca 2+ and K+ channels (step 5), which underlie
complex electrical activity, including trains of large amplitude
action potentials (APs) or long trains aborted APs riding on plateau potentials. The opening of high voltage activated (HVA)
Ca 2+ channels support rapid entry of Ca 2+ (step 6) and Ca 2+ dependent exocytosis of the contents of a small pool (at most
several hundred) if insulin granules in close proximity to the
plasma membrane (the readily releasble pool, RRP) (step7) and
likely recruit granules from more interior regions of the cytoplasm into the RRP to refill this pool.20 Individual APs repolarize as a result of opening of voltage-dependent K+ channels,
while plateau depolarizations are likely terminated by the opening of poorly voltage-dependent but Ca 2+ -activated K+ channels. Incretin messengers, such glucagon-like intestinal peptide
(GLP-1) released by enterochromaffin-like (EC) cells of the gut
epithelium sensing newly digested nutrients, and acetylcholine
released by stimulation of vagus nerve; both enhance closure of
K(ATP) channels and help recruit insulin granules into a release
ready pool.21,22 Current work is focusing on the contributions of
distinct electrical activity patterns, novel Ca 2+ currents, glucosederived second messengers other than ATP, and distinct subsets
of the RRP pools, including a low Ca 2+ sensitivity immediately
releasable pool (IRP) likely docked near clusters of Ca 2+ channels and a high Ca 2+ sensitivity (HCSP) likely farther from the
clusters of Ca 2+ channels, to the shaping of biphasic insulin
secretion.23-26
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Recently, Lacy’s early experiments on movement of insulin
granules have attracted intense interest. These approaches have
been improved and made more quantitative using enhanced
optical techniques (including evanescent wave or total internal
reflectance microscopy, confocal microscopy and two photon
excitation microscopy) for tracking the movement of near membrane granules up to the membrane and their subsequent fusion
with the plasma membrane and release of their into the extracellular space (ECS). Specific tags for exocytosis include red or
green fluorescent protein labeled peptides, including C-peptide
of derived from pro-insulin, intrinsic granule membrane proteins (syncollin, or phogrin), granule membrane attached proteins (tissue plasminogen activator), and even insulin bound
Zn2+ released into the ECS with decondensation of crystalline
insulin granule core and then detected by a bath applied fluorescent indicator.27-31 Endocytosis can be tracked by the filling of
granule exocytotic figures with otherwise excluded fluorescent
dextran, applied as a fluid phase tracer or with quenching of
pH-sensitive fluorescence on granule re-acidification after their
recapture. With simultaneous capacitance and amperometry
recordings from the same cell it is becoming possible to ask what
fraction of attempted exocytoses lead to exit of the crystalline
insulin (with its associated Zn 2+) into the extracellular space,
as opposed to more transient and restricted fusion pore formation with diffusion of more soluble contents, including peptides
such as C-peptide or small molecular weight molecules such
ATP and GABA.32 The latter two likely play autocrine or paracrine regulatory roles in the islet rather than true endocrine roles
systemically. As anticipated by Lacy, some evidence suggests
that “newcomer” granules, perhaps refilling the HCSP, are the
major contributors to second phase insulin secretion. Careful
application of these approaches may yield evidence as to whether
granules from distinct granule pools differentially release soluble
vs. condensed contents, and how rapidly granule membrane is
retrieved and resorted.30,31
In addition, stimulus-secretion coupling by α-cells has also
received intensive study using single cell techniques presented
above. Outlines have emerged as to how tonic glucagon secretion results at very low levels of glucose and insulin, how glucagon secretion is curtailed in response to a post-prandial rise
in glucose and how glucagon secretion reappears at high levels
of glucose or in the presence of high concentrations of adrenalin.32-34 As shown in Figure 1B, α-cells exhibit similar K+(ATP)
channels as found in β-cells, though most are closed at low levels
of glucose. In addition, they have an abundance of non-selective cation channels, as well as standard voltage dependent Na+
channels and low voltage activated (LVA or T-type) Ca 2+ channels. At 2–3 mM glucose α-cells are depolarized and fire spontaneous action potentials that trigger Ca 2+ entry through LVA
Ca 2+ channels; as a result, they exocytose glucagon-containing
granules. Raising extracellular glucose towards or above 5 mM
closes down more K+(ATP) channels (step 1–3) and further
depolarizes the α-cells into a voltage range (near -35 mV) (step
4) where Na+ and T-type Ca 2+ channels are inactivated (step 5)
and AP amplitude is decreased or its activity even ceases, thereby
reducing Ca 2+ entry (step 6) and glucagon granule exocytosis.
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In addition, secretory products of the β-cell, including GABA,
Zn2+ as well as insulin, likely suppress glucagon secretion. The
best studied of these is GABA: it binds to and opens ionotropic
GABA-A receptor channels, which carry Cl- current and clamp
the membrane potential of the α-cell near the Cl- equilibrium
potential thereby reducing α-cells electrical activity and glucagon release. Lastly, at supraphysiological levels of glucose, where
all remaining K+(ATP) channels are closed, or where large concentrations of adrenalin is released by the chromaffin cells of
the adrenal medulla, HVA Ca 2+ channels are augmented, α-cells
may develop plateau depolarizations to -20 mV (step 5a) that are
sufficient to tonically activate HVA Ca 2+ channels and induce
Ca 2+ entry (step 6a) as well as recruit more granules into a readily
releasable pool, thereby promoting a phase of glucagon release
(step 7a), such as that seen during diabetic ketoacidosis or other
systemic stresses.
Much less is known about stimulus-secretion coupling in
somatostatin secreting d cells. Early reports (e.g., a recent one
using human cells) suggest that the resting membrane potential is dependent on sulfonylurea- but not glucose-dependent
K+(ATP) channels, that closure of the latter channels sets off
Na+ and Ca 2+ dependent action potentials, and that exocytosis
is Ca 2+ entry-dependent but slow to start and continuing for
up to a second after current through HVA Ca 2+ channnels has
ceased.35
The extensive effort at understanding the cell biology and
biophysics of stimulus-secretion coupling underlying normal
insulin secretion has yielded a better understanding of two rare
conditions congenital conditions.36-38 Congenital hyperinsulinemia of infancy is now thought most often to be due to the
loss of function mutation of K+(ATP) channels (hyposensitivity to MgADP). In contrast, neonatal diabetes, is now thought
most often to be due to gain of function K+(ATP) channels
(mutations of Kir6.2). However, the rather prevalent state of disordered insulin secretion in man, type 2 diabetes mellitus (DM
2) where β-cells of islets, though reduced in number, remain
largely intact, has been much less tractable. Some evidence suggests that in DM 2 β-cells have underlying variations in key
coupling factors in cell metabolism (e.g., glucokinase) or key
channel subunits e.g., SUR of K+(ATP). Other evidence suggests
that increases in free fatty acids (ffas), resulting from developing
obesity, may downregulate key regulatory features or even dissociate Ca 2+ channels from secretory granules.39 However, to date,
there has been no systematic study of glucose-induced depolarization, electrical activity or exocytosis in single cells from DM
2 islets. It is likely that progress will continue to be slow. DM 2
pancreases are not easily procured and often do not readily yield
their islets. Also, in a disease that progresses slowly, major heterogeneity in basic defects underlying pathophysiology, may be
present and superimposed on ageing-dependent “loss of vigor”
of key regulatory features. Lastly, as we have learned from type 1
DM, even the most promising of small animal models may not
really replicate the human disease.40 However, investigation may
be facilitated by cryopreservation/thaw of islets, which preserves
whole islet and single cell function, to promote storage, sharing
and comparative testing of available tissue.41
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In addition to enhancing our understanding of individual
endocrine cell types in the islet, studies begun by Lacy, and now
ongoing world-wide, have demonstrated just how interrelated
cells in the islet micro-organ are. Lacy’s early ultra-structural
work42 vigorously continued by Orci and collaborators, demonstrated complex endocrine-endocrine cell and endocrine cellendothelial cell contacts implying complex “social interactions”
of component cells. These include contiguity of β-cells with
α- and δ-cells, inter-β cell gap junctions, structural polarization of β-cells between capillaries, and alignment of complex
endothelial cell pores with regions of preferred exocytosis in
β-cells. Electrophysiological studies have shown that electrical
coupling of β-cells contribute to their co-ordinated electrical
activity43 while secretion studies on single β-cells vs. those in
small clusters have demonstrated the supra-linear augmentation of secretion resulting from cell-cell coupling. Furthermore,
studies of the functional islet microvasculature have provided
evidence for differential perfusion of islets. In many species the
afferent circulation burrows into the core of the islet, where the
majority of β- and δ-cells reside, and then branches as to return
to the mantle where the majority of α-cells reside. This anatomical organization should permit β-cell secretions to inhibit
α-cell secretion of glucagon and δ-cell secretion of somatostatin
to inhibit both α- and β-cells.
Using an idea proposed by Snell in 1957 to explain the delayed
growth or destruction of weakly antigenic transplanted tumors,
in the early 1980s Lacy championed the concept of long-distance
interactions between cells of the islet micro-organ and the immune
system.44,45 The major immunological players in this interaction
are (1) immune surveillance cells traversing the islet and recognizing unusual or foreign antigens and (2) immune affector cells
returning from lymph nodes with instructions to damage or kill
cells bearing the unusual or foreign antigens. Simply put, Lacy’s
idea was that presentation of allo- or auto-antigens by the wandering “passenger leukocytes,” now called dendritic cells/macrophages (or DC/MΦs) was critical for both autoimmunity of type
1 diabetes mellitus and islet transplant rejection, respectively. In
the case of autoimmunity of diabetes, the autoantigens bound
by the major histocompatibility complex (MHC) at the surface
of the DC/MΦs were thought to be present at the surface of the
β-cell. Contemporary candidates range from insulin, to processed
viral antigens that mimic other β-cells proteins e.g., Coxsackie
enterovirus antigens mimicking peptides derived from glutamic
acid decarboxylase (GAD 64), or rotovirus antigens mimicking peptides derived from tyrosine phosphatase Ia (reviewed in
ref. 46). In the case of islet transplant rejection, the alloantigens
were thought to be present on the surface of capillaries of the allografted islet. Ultimately this leads to local activation of specifically pre-selected cytotoxic lymphocytes (CTLs) in the draining
lymph nodes causing them to home in on the islets, destroy target
cells and reduce islet function.
Passenger macrophages have come of age.47 Our current understanding is that when new specific antigens appear
at the surface of foreign capillaries or b-cells undergoing
destruction, they are taken up and processed by DC/MΦs
(see Fig. 2). Antigen processed in the lysosomal pathway is

Figure 2. Immune responses evoked by b-cells: concept of passenger
leukocyte (dendritic cell/macrophage, DC/MΦ) as key intermediary in
the development of islet autoimmunity and islet transplant rejection.
See text for discussion. More recent evidence suggests that the homing
of CTLs specific for insulin results from the presentation of antigen
(insulin fragments) by endothelial cells.

ultimately presented on MHC Class II sites on these cells,
while antigen processed in the proteosome pathway is presented
on MHC class I. Surface antigen presentation converts immature, tolerogenic DC/MΦs to mature immunogenic DC/MΦs.
After migration to local lymph nodes, mature DC/MΦs, via
their liganded MHC class II sites and co-stimulatory sites bind
to clonally selected sentinel (CD4 +) T-helper (TH) cells, which
express on their surface T-cell receptors (TCR) for MHC class
I-peptide complex and co-stimulating molecules. The binding
of surface T-cell receptors (TCRs) converts members of the TH
cell population from a largely regulatory to a largely autoreactive
phenotype (TH1), which begin to divide and secrete inflammatory cytokines, such as IFNγ. In addition, mature DC/MΦs via
their MHC Class I/peptide complex also to CD8 + cells. The latter, plus the cytokines secreted by the activated TH1 cells, promote the maturation of CD8 + cells into cytotoxic T lymphocytes
(CTLs).
During their circulation, the CD8 + -derived CTLs are
attracted into islets by chemokines released by the local inflammatory response to b-cells and as well as by MHC Class I/peptide complexes expressed on the surfaces of b-cells themselves.
CTL form “immunological synapses” with the b-cells, thereby
promoting b-cell apoptosis, secondary to release of granzymes
and channel-forming perforins.
Lacy’s “reduced model of islet function and dysfunction”:
A bit of oral history concerning some assumptions underlying
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the vision of islet transplantation. “I’m a simple pathologist; I
believe what I can see and touch.” (Paul Lacy, September 1987).
That’s how Lacy began describing the concept of islet function
that guided his work in our first extended conversation in 1987.
Admitting it didn’t encompass all that was known about islets,
he thought it was fairly simple and utilitarian: “good for a practicing pathologist and would-be transplanter.”
Lacy conceived of islets of Langerhans as microperfused and
autonomically innervated micro-organs containing at least three
different types of endocrine cells each intercommunicating
via intimate contacts and internal vasculature; this idea would
later be called by Pipeleers “the bio-sociology of the islet”.48
However, Lacy saw the β-cell as the key cell in the islet because
its hypoglycemia-inducing secretion, insulin, unlike the α-cell’s
hyperglycemia-inducing secretion, glucagon, could not be duplicated by any other hormone (such as adrenaline). Lacy was
convinced that the β-cell’s unusual biphasic response to a sustained rise in glucose was critical to its function. An early spike
of insulin secretion, lasting 5–10 minutes, from a small pool
of “emiocytosis-ready” insulin granules, was critical in saturating insulin receptors in liver and causing a decrease in glucose
release from, and increase in glucose entry into that depot store.
An ever increasing second or dome phase of insulin release, lasting up to hours, from a more slowly mobilized pool of maturing
insulin granules, traveling along microtubules to the vicinity of
plasma membrane surface49,50 was critical for steady state glucose
uptake into muscle and fat. He recognized that insulin secretion
was primed by the digestive tract via both a vagal reflex and
endocrine secretions from gut lining. However, since biphasic
secretion was preserved after islets were isolated into a denervated, non-perfused state and even after they had spread out into
a monolayer in culture, Lacy conjectured that from a practical
standpoint, if an islet were in a “safe, well perifused place” innervation, incretin priming and even intact internal capillary beds
might not be essential for the maintenance of an intrinsic secretory pattern.
Lacy saw islets and islet cells as “plastic” rather than static tissue. Over their extended function, islets would need to expand
during developmental demand for increased insulin output (e.g.,
pregnancy) probably through hypertrophy. Also being a tissue
with high metabolic turnover, some cells would get worn-out
and need to be replaced with new ones, probably through the
infrequent mitoses of the healthiest cells.51 In fact, in experimental diabetes produced by partial pancreatectomy of the
growing rodents, symptomatic disease only developed after the
need for insulin outstripped the ability of the remnant hypertrophic islets to secrete it in a hyperglycemic environment.52,53
In contemporary parlance this is now called “functional islet
reserve”.54 Hence, protecting the function of islets on a longterm basis required a sufficient complement of functioning islets
to maintain near physiological circulating glucose and prevent
the exposure of islets to prolonged hyperglycemia. However,
he saw no reason why these processes would not occur even in
environments foreign to islets provided the islets were in contact
with the bloodstream and remained metabolically intact.
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Lacy viewed isolated islets, lacking surrounding acinar tissue,
as potentially poorly antigenic, provided passenger immune cells
could be removed from islet vasculature and intrinsic endothelial
cells were lost or replaced by “host” endothelium as functional
capillary supply was re-hooked. (This assumption has finally
been tested experimentally and supported.55) Hence, given a
choice of transplanting a whole pancreas, which required vascular anastomoses that could immediately clot, as well as complex
exocrine drainage exocrine draining, vs. transplanting isolated
islets into accessible site, in his opinion the latter was clearly
more preferable.
Lastly, Lacy viewed the generalized dysfunction in diabetic
mellitus from a “β-cell-centric” perspective, one that was not
nearly as popular before the mid-1990s as it is now. That is,
if dysglycemia were controlled sufficiently early on most of the
long-range consequences of diabetes, including retinopathy,
neuropathy and nephropathy, might be prevented, ameliorated or even partially reversed. However, he thought that fine
regulation of serum glucose could only achieved with a rapid
feedback-controlled system requiring glucose-recognition by
the insulin-dispenser emptying directly into the central blood
stream, where it is needed, rather than into peripheral sites such
as skin, where it would only be slowly absorbed. Hence for him
islet transplantation into vasculature, or sites capable of intense
vascularization, would be the most preferable source of insulin
administration and the most physiological approach for insulin
replacement therapy. Since long-term poor glucose control bred
islet dysfunction, it would be necessary to transplant a full complement (literally a “pancreas’-worth”) of well-functioning islets
and to have as many of them as possible continue to function for
as long as possible.
Hence, for Lacy there were three essential prerequisites for
islet transplantation. By the late 1980s good progress had been
made towards satisfying at least two of these.
(1) “Islet greediness” or the efficient harvest, in minimally ischemic fashion, as many islets as possible from a donor pancreas and
then “ keeping as many as possible, as happy as possible, for as long as
possible.” In the case of “islet harvest” from large animal pancreases, the solution was an ingenious bipartite isolation perfusion
chamber designed by post-doctoral fellow Camillo Ricordi56
in to which the enzyme-infused pancreas was placed. By 1988,
Ricordi, Scharp and Lacy were able to isolate as many as 800,000
islet equivalent from pancreatic of brain-dead human donors and
nearly 400,000 islet equivalents from canine and pig pancreases.
Islet preparations from these species were often >90% pure, and
>90% viable, as assessed by light refraction and vital dye exclusion. Furthermore, in vitro islets of all species functioned well
during perifusion as well post-transplantation even after several
weeks in low temperature culture or after cryopreservation/thaw.
(2) Delivery of isolated islets to an easily accessible quasi-pancreatic site. Soon after the first successful high yield isolations
from rodent pancreases, Ballinger, Scharp and Lacy57 began
their heroic efforts of transplanting small quantities of islets into
a variety of sites: under the capsule of kidney; under the capsule
of spleen; intra-peritoneally, on the omentum; and later even
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intratesticularly.58 The first experiments, in which islets were
placed under the capsule of the kidney, demonstrated “proof of
principle” that islets could secrete insulin and restore glycemia to
syngeneic rats treated with streptozotocin, a b-cell specific toxin.
While technically a 2–3 ml volume of packed islets, obtained
from a human donor, would easily be accommodated under
the capsule of a single human kidney, practically subcapsular implantation required major surgery. Hence a less invasive
approach to clinical islet transplantation was desirable. In addition, Lacy realized that insulin secretion into a site where first
phase release would affect early uptake of glucose by liver was
highly desirable from a physiological standpoint.
In 1973 Ballinger, Scharp and Lacy first reported the reestablishment of near euglycemia and normal fasting insulinemia in streptozotocin-treated rats by injection/embolization
of 400–600 hand picked, syngeneic islets in the portal vein,
where glucose-avid hepatocytes would have primary access to
glucose for rapid deposition as glycogen. Furthermore, within
2–12 weeks, polyuria, polydypsia and hyperglycemia were abolished and thereafter islets sustained their function for many
months. Histological, long term transplanted islets (>5 months)
contained well granulated α-, β- and δ-cells that projected
across the vascular space formed and formed direct contacts and
even functional complexes with hepatocytes.59 In fact, neighboring hepatocytes showed increased glycogen and lipid deposits.
(Quite recently this finding has been shown to have clinical
implications in that in human patients who have received infusion of islets into the portal vein, the delayed development of
regions of hepatic steatosis has been used to track the presence
of functional islets.60) By the mid-1980s clinical interventional
radiology was nearly ready to tackle tissue infusions into human
portal veins. However, the key piece of data missing from all
of the islet transplantation trials in animals, and only provided
years later,61 was a detailed study of the metabolic state of the
transplanted islets, including their oxygen consumption, and
their abilities to undergo biphasic insulin secretion and to revascularize. As discussed below, this turned out to be truly critical
issue in the preparation and survival of islet transplants.
(3) Making islets non-immunogenic. In early rodent experiments, transplantation was performed syngeneically (between
genetically identical individuals) or into a host with little capacity for transplant rejection. To further reduce the probability of
rejection a single does of anti-lymphocyte serum or monoclonal
antibody was infused into the host prior to transplant. However,
for transplantation into a non-immunocompromised host of nonidentical genetic background, either islets had to be rendered
non-immunogenic or clinical immunosuppression would be
needed. Lacy’s vision did not include chronic immunosuppression because he was fully cognizant of the vast array of systemic
side-effects of contemporary immunosuppressants as well as their
potential for very specific effects on islet metabolism. Lacy was
convinced that “islets, as metabolic factories, won’t thrive with
high doses of catabolic drugs like corticosteroids nearby”.
Lacy spent much of the 1980s developing approaches to
reduce islet immunogenicity by attempting to deplete isolated islets of dendritic macrophages (DC/MΦs) and remnant

capillary endothelial cells. His approaches, including extended
culture of islets at subphysiological temperatures and/or high
oxygen tension, treatment with anti-dendritic cell antibody as
well as islet cryopreservation and thaw were not only seminal in
islet transplantation but also in raising general “immunological
consciousness” about dendritic cells. Currently, making donor
islets less immunogenic and recipients less reactive remains a
field of active bench-to-bedside inquiry.62
Part II: The Practice of Islet Transplantation
to Cure Diabetes
The experience of the first 20 years. The proof of practicality
of all great visions resides in the details of the success of wideranging daily application. Concerning islet transplantation,
Lacy, ever the ebullient public enthusiast, remained the private
cool-headed realist. He knew that rodent “diabetes” was not
human diabetes mellitus and believed that the transition of islet
transplant from short lived, inbreed caged rodent to long-lived,
free ranging and genetically diverse man would be difficult.
However, he also freely admitted that the only way to investigate
and circumvent the shortcomings of human islet transplantation
was to perform the “in vivo” human experiments and take what
was learned at the bedside back to bench for improvement. In
addition he noted that “what’s worth doing never comes easy.”
Nevertheless, by the late 1980s, a little over a decade after he
authored a master plan for clinical islet transplantation,63 Lacy
supervised the first partially successful transplantation.
By infusing, via an umbilical vein catheter, 800,000 nearly
pure islets, harvested from 1.4 pancreata of brain dead patients,
into the portal vein of an insulin-dependent diabetic renal
transplant patient, already immunosuppressed with low doses of
cyclosporine and prednisone, his team succeeded in maintaining
the patient off exogenous insulin for 12 days.64 Within months,
protégés, such as Ricordi, achieved more long term success with
larger infusions of islets into other renal transplant patients
treated with a steroid-free immunosuppression regime based on
tacrolimus. In spite of the continuing dearth of tissue supply and
the need for immunosuppression, the arduous race for the cure
was on. Spurred by bursts of euphoria, especially one engendered
by the “Edmonton protocol” utilizing sirolimus + tacrolimusbased, steroid-free maintenance immunosuppression occurred.
Repeated infusions of a pancreas’ worth of freshly isolated islets
to brittle (hypoglycemia-prone) insulin dependent type 1 diabetics (DM 1) without renal allografts,65 were also attempted.
To date, nearly a thousand patients have been transplanted with
varying success using variants of the techniques presented the
seminal paper by the Lacy team. We shall review this limited
success, the clues these surgical “experiments” have offered us
about engrafting islets, and how the return from bedside back
to bench has allowed valuable clues to be tested individually and
rigorously.
The most active islet transplantation centers (Edmonton,
Miami, Minnesota and an international consortium) have
reviewed their results after adoption of the Edmonton protocol
now including daclizumab induction.66-68 Transplanted patients
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as a group had DM 1 for an average of 25 years, were of near
ideal weight, had at least 50% normal creatinine clearance and
experienced recurrent, severe hypoglycemia. Pancreases used as
tissue sources were generally selected for cold ischemia time of
less than 12 hours. The initial transplants consisted of 400,000
islet equivalents (IE) (∼5–10 cc of tissue of 30–90% islet purity),
either freshly prepared or cultured for 24–72 hours, and determined to be both bacteria- and endotoxin-free. Transplantation
was achieved by percutaneous transhepatic intraportal infusion
of a small volume of heparinized solution. Up to two booster
infusions were later given bringing the average cumulative total
to 800,000 IE.
While 44–82% of patients were insulin independent at the
end of the first year, only 7.5% remained so at the end of the
fifth year, despite apparent 80% graft survival as determined by
C-peptide secretion. Never-the-less, patients returning to insulin dependence had better glycemic control (HbA1c 7 vs. 9) with
fewer episodes of hypoglycemia, the latter due to either reduced
insulin requirement, improved glucose counter-regulation or
some correction of symptomatic awareness of hypoglycemia.
Chronic complications in transplanted patients included mouth
ulcers, anemia, diarrhea, ovarian cysts, acne and increased need
for treatment with antihypertensives and cholesterol lowering
statin drugs. In addition, there were tendencies towards worsening of renal function and development of proteinuria, perhaps
as a result of the immunosuppressive drugs used in the face of
underlying diabetic glomerulosclerosis. Also, development of de
novo donor specific antibodies in patients on continued immunosuppression, raised concerns about possible predisposition
to worsened outcomes in subsequent major organ transplants.
In spite of case reports (reviewed in reference 69) there are no
controlled studies to indicate whether islet transplantation slows
progression of long-term systemic complications of DM such as
cardiomyopathy, macro- or micro-angiopathy, proliferative retinopathy, or peripheral/autonomic neuropathy. Hence results to
date have caused some to question whether islet transplantation
is ready for “prime-time” or just remains experimental and properly reserved as adjunctive therapy to renal transplantation in
brittle diabetics with end-stage renal disease.
More fundamentally, the rapid declines in islet function
post-transplant have caused even the key enthusiasts to reexamine the original vision more critically. However, as with
all important new therapies, severe challenges tend to provoke
useful responses. In the case of islet transplantation, perhaps
the most intriguing challenge is the issue of whether, as Lacy
had originally speculated, immunosuppression, might be
the true limiting step or Achilles’ heal of the entire process.
Specifically, recent data suggest that in test organisms (and
perhaps patients) with a history of autoimmune DM, T cell
depletion produced by immunosuppressives such as FK and
rapamycin might indirectly result in the homeostatic expansion of the remaining T-cells, such as those autoreactive to
the β-cell, and thereby cause a recrudescence of autoimmune
DM, now however masquerading as transplant failure. If so,
should patients be specifically chosen for lack of recurrent or
recent autoimmunity? Alternatively, would pre- or concurrent
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drug treatment of recipients to reduce memory T cells prevent
expansion of anti-islet autoreactivity?
What islet transplantation has further taught us about the
islet as a micro-organ. Islet transplantation is still “a work in
progress.” 70,71 In retrospect, the overwhelming concern with
obtaining sufficient islet mass for transplantation had caused
“myopia” in the early transplant vision. On the one hand, there
was a general lack of intimate knowledge and standardization
of the metabolic state of islets being produced from the source
pancreases and then transplanted after variable time in culture.
On the other hand, there was little understanding of the stability of the islets as micro-organs outside of their physiological
milieu and especially in the portal vein. For example, traditionally there was nearly universal reliance on optical measures for
quantitation immediate “viability,” loose standards for quantitation of yield (the islet equivalent), and, at best, modest standards for effective “in vitro” secretion after acute culture (2- to
3-fold increases vs. >10-fold increase in the best quality islets).
All of this led to the acceptance of mediocre quality tissue for
transplantation. With the US Food and Drug Administration
demanding quality assurance and standardization of the transplant “product or device” prior to its infusion, these features
are now under active scrutiny from both the retrospective and
prospective point of view. The condition of the pre-transplant
islet and its dependence on the quality of the source pancreas as
well as the treatment of islets during and after harvest are now
tracked by every transplantation center.
In the case of the pre-transplant islet, first it was necessary to understand pre-harvest, which source of pancreases are
most likely to prove the best tissue sources. Variables include
donor age, adiposity, insulin reserve, and potential injury in
the immediate pre-harvest state (e.g., during cytokine storm
with brainstem death). There is general recognition of a central
conundrum in islet harvestment: islets from the pancreases of
young (<35) and lean donors, likely to be the most robust islets,
are technically difficult to isolate, while those from pancreases of
older (>50) and obese donors are somewhat larger and easier to
liberate. Second, it was critical to minimize cold ischemia time of
the pancreas both pre- and post-isolation. While islets are highly
metabolic and do poorly under hypoxia, pancreases used for islet
preparations are very often “left over” organs, offered for harvesting after of heart, kidneys and lungs have been obtained or
after the pancreas has been rejected for whole organ transplantation. Cold ischemia time is often well beyond an optimum
of 6–8 hours. Recent improvements include the use of oxygenated fluorocarbon solution transport. Moreover, the potency of,
and exposure time to, enzymes in the islet isolation solutions,
needed to be standardized and insured. Lastly, beyond the general consideration of whether the best islet products are shaggy
vs. round and nearly fresh vs. cultured for several days, there
was a critical need for individual aliquots of islets to be carefully
evaluated and standardized prior to transplantation. Advances,
which may prove critical to the standardizing harvested islets,
are the rapid use of laser scanning cytometry and measurement
of O2 consumption on exposure to glucose to characterize islets,
fluorescent-activated sorting of islet cells and optical assay of
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Figure 3. Complexities and hidden pitfalls inherent in islet transplantation, especially into the portal circulation. (A) The islet’s sheltered, nurtured
existence in its native environment, where its intrinsic microcirculation is intact, its portal circulation allows it to increase its blood flow by borrowing
from acinar supply post-prandially, and its intrinsic replenished with cells or replacement as a micro-organ, when worn out. (B) The islet’s precarious
situation as a “stranger” post-transplantation (see text box legend).

mitochondrial membrane potential in product β-cells, and rapid
assessment of insulin release by single islets using microfluidic
perfusion chambers and secretion assays other than the very time
consuming radio-immunoassay.
In the case of the transplanted islets, especially ones introduced
into the portal vein, their post-transplant courses appear far from
smooth. Following Paul Robertson’s apt description, there is
increasing evidence that the islet in the portal vein is a “stranger
in a strange land” and suffers on a number of accounts (see
Fig. 3). However, increasing recognition of key issues has stimulated a variety of approaches to ameliorating some of them.
(1) Ischemic damage during procurement or culture results
in an initial dearth of functional islets; a conservative estimate
is that 30% of islets have necrotic cores at the time of infusion.
(2) Immediate islet loss due to coagulation induced by tissue factors resulting from islet prep impurities (acinar and duct
fragments) or portal vein thrombosis resulting from vessel injury
during infusion.72,73
(3) Ongoing loss of 30–40% of viable islets after introduction
into the portal vein, even in the absence of portal thrombosis.
An instant blood-mediated inflammatory/thrombotic reaction
(IBMIR) has been identified,74 where stress + hypoxia-induced
surface and soluble tissue factor, a cytokine receptor subfamily,
results in expression of FVIIa, and macrophage chemoattractant
factor. This results in platelet coagulation, complement activation

and leukocyte infiltration of islets. In addition, hepatocyte and
produces Kupffer cell activation and damages islet cells via
INOS and cyclooxygenase 2 generation, even in absence of portal
thrombosis. There is encouraging evidence that this reaction may
be inhibited, among other ways, by preincubation or co-administration with nicotinamide and inactivated TFVIIa and or by
coating islets with autologous endothelial cells (obtained from
peripheral venous scrapings and expanded in vitro to coat islets).
(4) Rapid onset of apoptosis may be induced by several factors. The combination of IBMIR and apoptosis may produce loss
of 70% of infused islet tissue in 3 days. Here again, genetic and
pharmacological inhibition has been possible in the forms of ex
vivo transduction of islets with X-linked inhibitor of apoptosis
(repressor of terminal caspase pathway).
(5) Functional revascularization and its maintenance. Data
from rodents suggests that long term, even under the best conditions in syngeneic rodents, less than 75% of transplanted islets
remain intact. Islets retrieved from any engrafted site displayed
decrease oxidative utilization of glucose, decreased insulin contents, and decreased regulated insulin release. However, intrapancreatically-transplanted islets seem to suffer the least while
intraportally-infused islets seem to suffer the most.75 Islets recovered after intra-portal infusion often have poorly perfused cores,
with intra-islet pO2 being 5–10 torr after implantation into the
portal vein vs. 40 torr in the intact pancreas.76 Tissue hypoxia
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may acutely raise cytosolic [Ca 2+] and contribute to constituitive insulin release, while decreasing glucose-induced insulin
release, which requires vigorous aerobic, including mitochondrial, metabolism. Moreover, long-term this hypoxia may be
detrimental to survival of β-cells predisposing them to stressinduced apoptosis, especially as β-cells lack a hypoglycemia/
hypoxia inducible mitochondrial inner membrane protein that
protects other cells that rapidly oxidize glucose, such as neighboring α-cells and cardiac myocytes.77 In humans and nonhuman primates, islets introduced into the portal circulation
become enveloped in thrombus and then are slowly incorporated subendothelially in the vessel wall to be revascularized by
the vaso-vasorum.75 This long term revascularization, achieved
by an arduous, islet-threatening process, is likely to be suboptimal, in spite of evidence that islets secrete angiogenic factors,
such as vascular endothelial cell growth factor-A (VEGF-A)
and angiopoietin-1. Two novel approaches focusing on improving the islet vascularization are being developed. The first is
based on tissue engineering and consists of co-culture of islets
with bone marrow derived mesangial stem cells and endothelial cells to provide adequate source of angiogenic factors as
well as promote invasion of endothelial cells and the sprouting
of chimeric vessels from the islet. The second is pre-transplant
treatment of islets with prolactin, a known angiogenic stimulant
to islets.78
(6) Loss of neural innervation prevents the neurally-mediated
increase in islet perfusion during increased oxygen demand of
glucose utilization occurring with stimulus-secretion coupling.
This is likely not reversible given the geography of transplanted
islets.
(7) Poor islet cell proliferation combined with unlikely islet
neogenesis should militate replacement of apoptotic b-cells and
result in progressive decline in the number of functional islets.
Clinically, attempts at slowing apoptosis and promoting islet
neogenesis in patients with chronic allograft dysfunction have
included administering exenatide, a long-acting analog of GLP-1.
In the future magnetic resonance imging, now being developed with targeted iron oxide “contrast agents” for use in rodents,
may permit monitoring of islet engraftment and vascularization,
immune rejection, glucotoxicity and the role of islet purity in
ultimate longevity, thereby helping to evaluate current, as well as
predict future, allograft function.79
What auto-transplantation of partially purified islets and
whole pancreas transplant have taught us about the islet as a
micro-organ. In addition, valuable lessons have been learned
about the viability of the islet as a micro-organ when the results
of transplantation of purified islets are compared with two other
replacement techniques. They are (1) auto transplantation of
pancreatic tissue, in patients with chronic pancreatitis and (2)
simultaneous renal pancreatic transplantation, in diabetics with
renal failure two competitor islet replacement techniques. First,
from the experience of the Robertson’s group it is clear that rapidly prepared, partially purified islet harvests autotransplanted
into the portal vein can provide of reduction in fasting glucose
for as long as 13 years. Here reduction in glycosylated hemoglobin is highly correlated with the mass of initial islet infused.
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Glucagon secretion in response to arginine, but not to hypoglycemia, is also well preserved.80 From this experience, as predicted by
Lacy, the functional quantity of transplant mass is critical to its
subsequent success and, as suggested by the islet transplantation
studies, the portal circulation might be less than ideal for stable
counter-regulatory function in glucose control. Surprisingly,
in light of Lacy’s reduced model of islet function, the mass of
co-transplanted acinar and ductal tissues did not seem to be an
impediment to subsequent islet function. Perhaps the trade-off
point, between the trauma of islet purification and the avoidance
of potential for tissue inflammatory response by less extensive
purification of islets, needs to be shifted. As suggested by tissue
culture studies, including those of pancreatic discards after islet
isolation,81,82 cells within fragments of ductal and acinar tissue
liberated from their restraining matrix, might actually transdifferentiate and bud off islets, or else secrete factors that protect
islets or enhance their revascularization during hyperglycemia.
Interestingly, when the Edmonton group carefully compiled the
characteristics of infused islet tissue and compared this with the
survival of the subsequent transplant, after two years transplantation they found a significant positive correlation between the
function of the intra-portally administered allografts and the
number of ductal (cytokeratin-19 positive) cells in the infusate.
In the same study, optical estimates of islet purity did not correlate well with insulin staining of tissue and long-term outcome
of graft did not correlate well with post-isolation in vitro glucoseinduced insulin secretion.
Second, despite the feared arduousness of the procedure,
beginning in the 1990s pancreas transplantation became generally successful. New techniques for organ harvesting reduced
exocrine damage; bladder drainage of ductal secretions permitted easy of assessment of amylase secretion as an index of
exocrine function; subsequent enteric drainage avoided complications of intermittent metabolic acidosis and volume depletion;
and improved HLA matching and immunosuppressive regimes
(based on tacrolimus, rather cyclosporine), improved graft survival.83 Simultaneous renal/pancreatic transplantation had threeyear survival rate of 70–80%, or similar to most other types of
organ transplantation, and provided a means of effective control of glycemia and autonomic insufficiency. Solitary pancreatic
transplantation could reverse lesions of diabetic nephropathy and
as well as macro-vascular changes. In this case Lacy may have
been too pessimistic: in the face of well-preserved islet mass and
adequate attachment to central vascular supply, a limited degree
of chronic rejection and cytotoxicity from immunosuppressant
therapy may not be as swift and potent islet killer as he suspected.
Part III: Looking Over the Horizon at Emerging
Alternative Approaches and Perspectives
on the Roads not Taken
My second extended conversation with Lacy occurred in 2000
in one of his visits to Washington University after his retirement from active scientific inquiry. Lacy was now the thoughtful
contributor to advisory boards in academia and industry and
an elder statesman in the ever expanding diabetes community.
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His views were much more philosophical. As far as curing diabetes by islet transplantation, he realized that several limiting
problems had emerged. These included the likely insurmountable problem of scarcity of human tissue; the vagaries of immunology and immunosuppression; and the nagging complexity of
transplanting this “simple” micro-organ, including whether the
portal vein was an ideal target site. While he had considered
alternative sites for transplantation, including intraperitoneal
(omental) and even intramuscular, paralleling its increasingly
use for parathyroid transplantation, he was more concerned
that realistically transplantation would probably require a new
approach: use of encapsulated surrogate islet tissue. However,
he voiced a more fundamental concern: over the length of his
career the scope of diabetes had changed from an autoimmune
disease of a few immunologically unfortunate individuals into
an environmentally induced epidemic of over-calorization in a
sedentary population,84 an impending public health catastrophe
that no program of islet replacement would effectively serve. Put
another way, in 50 years, the bad genetic background underlying
the bulk of diabetes had shifted from the tendency toward autoimmunity, which always made life miserable, to the tendency
towards metabolic thriftiness, which in the past undoubtedly
had a clear selection advantage. Though in no way discounting
DM 1 as a major disease, Lacy wondered how drastically different his career in diabetes research would be if he were starting
out in 2000. Would he largely be investigating how to prevent
islet toxicity due to chronic, excessive nutrient fuel rather than
trying to replace islet function? To conclude this tribute we shall
refer to some of Lacy’s thoughts, as well as recent developments,
concerning these areas.
Identifying a surrogate transplant tissue for an alternative
transplantation approach. If not human islets for transplantation, what then? As we have emphasized, Lacy subscribed to the
following working definition of β-cells: a cell population that
(1) senses glucose over a physiological range of 3–7 mM and
responds by secreting insulin, (2) interacts appropriately with
glucagon-secreting α-cells and somatostatin-secreting δ-cells
and (3) regulates its own mass by precisely balancing of mitosis
and apoptosis over years while still being capable of undergoing an occasionally growth spurt (such as in pregnancy). Hence
β-cells could only be replaced by β-cells. If scarcity of human
tissue was the critical issue, this could be circumvented with
xenotransplantation using stable islets from pigs, which are
long-lived organisms with lower sensitivity to destruction by
autoimmunity85,86 and whose insulin, differing from human by
only 1 amino acid, had been successfully used to treat diabetics
for decades. At this time he preferred xenotransplantation to de
novo tissue engineering using transformed clonal cell lines or
elaborated stem cells and perhaps even to tissue extracted from
life-support brain dead humans. Specifically he thought that
pigs could be raised in a sterile environment (now in development in Minnesota and New Zealand), screened and genetically
modified to reduce risks of xeno-zoonosis.87 The ability to harvest pancreases from health animals rather than life-supported
cadavers would substantially reduce the problems of using ischemic, cytokine-activated tissue likely exposed pre-harvest to a

variety of pathogens difficult to test for, wide fluctuations in
pre-harvest organ perfusion and the possible effects intravascular coagulation causing micro-angiopathy. The issue of islet
xenoimmunology and transplantation might be addressed (1)
by genetic engineering to produce organs that minimize host
immune or (2) by “immunoisolation” of transplanted tissues.
“Knock out the enzymes that trigger reactions or surround the
islets with a semi-permeable membrane giving them access to
nutrients but not antibodies or immune cells. Then hopefully
they will secrete small molecules like insulin and not be a source
of retrovirus or oncogenes.” Currently, it is possible knock out of
a 1,3 galactosyltransferase,85 an antigen responsible for antibody
response and to engineer inhibitors of the complement system
cascade. Lacy was enthusiastic about encapsulation of islets in
a selectively permeable matrix.88,89 “With introduction into the
peritoneal cavity, they could even be retrieved and exchanged
for new ones if they simply wore out.” The major question in his
mind was whether to use embryonic, foetal, neonatal or young
or adult pigs as islet sources. Lacy’s new vision of islet transplantation was actually addressing two “brave new world” areas,
xenotransplantation and encapsulation, which have gained
increasing interest of the past decade.
In the early 1990s, Lacy and Scharp,90 along with similarlyminded investigators, had begun work on islet encapsulation.
Since the mid-1990s, individually encapsulated islets (in microspheres) or small clusters of encapsulated islets (in cylindrical
diffusion capsules) had been introduced free into the bloodstream or into the peritoneal cavity. Since then, islets have also
been seeded onto hollow fiber semi-permeable membranes to
form a bio-hybrid device resembling a modern dialyzer and
perfused as an arteriovenous shunt.89 Generally, the encapsulating medium has consisted of a biocompatible alginate whose
surface is cross-linked with calcium to form capsules that are
then coated with poly-L-lysine (PLL). Key problems using this
approach have been loss of islet function and continuing need
for immunosuppression, two likely related phenomena. Over
time, the beads often collapse, and the PLL permits growth of
fibroblasts attracting CD4 + T cells, B cells and macrophages and
causing the accumulation of cytokines, chemokines, complement and immunoglobulins, all of which impair function of the
encapsulated islets.91 While implantation of these capsules has
improved glucose control in animal studies, it often proved difficult to demonstrate significant insulin secretion by retrieved
beads. However, there has been recent good news in the form of
better understanding of why encapsulated islets are poor secretors as well as the design of better beads.
Transplantation of porcine islets in the absence of encapsulation has also been examined, with resultant reports of prolonged
reversal of diabetes reported in non-human primates after intraportal infusion of either adult or neonatal porcine islets.92,93
While heavy immunosuppressive targeting of T cells was used
to delay eventual T-cell mediated rejection, genetic engineering to eliminate hyper-acute rejection of solid organs, was not
attempted. The ability to make pig transgenics, however, suggests that IBMIR might be “engineered away”. The issue of the
relative advantage of neonatal vs. adult islets remains: while
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neonatal islets do not function immediately, they are less immunogenic and have potential for growth. Encouragingly, thus far
no transmission of porcine endogenous retroviruses has been
reported.
Finally I took the risk and asked about his views of the then
developing research with cell based therapies for β-cell replacement: engineered clonal β-cells or harvesting/differentiating
stem cells to be β-cell-like. His responses were bits of wry skepticism delivered in a mildly irritated tone. First, he asked how
trustable one might expect a tumor cell to be regarding slow
reproduction and stably secretion vs. reversion to uncontrolled
proliferation and unpredictable or episodic secretion. Second,
he asked how one would actually identify the stem cell for an
adult β-cell and if one started far back in development would
one simply be growing foregut teratomas for “a heck of a long
time before figuring anything out.”
However, over the past ten years substantial progress has been
made on harvesting/differentiating/engineering β-cell-like entities. While I’d anticipate Lacy would still have a healthy skepticism regarding these endeavors, he’d probably maintain a real
interest in them. Certainly, he’d be very pleased to learn of new
evidence supporting his contention that the best way to replace a
β-cell is with another real β-cell. Based on genetic linkage tracing analysis, the major source for steady state b-cell replacement
as well as proliferation after partial pancreatectomy, or targeted
ablation is from extant ones by simple cell division. Furthermore,
it is now proposed that cell division is the source of islet mass
expansion in pregnancy, after gastric bypass surgery, and perhaps in partial reversal/recovery from autoimmune diabetes.94,95
Unfortunately, it has also become clearer that currently used
immunosuppressive drugs inhibit regenerative restoration of
reduced β-cell mass by cell division. However, being an astute
biologist, he’d likely anticipate that there is still some room for
a facultative endocrine progenitor cell in the adult pancreas.
With partial pancreatic duct ligation causing acinar degeneration and duct proliferation, cells expressing the transcription
factor neurogenin-3 (NGn3) can be harvested and then injected
into explanted embryonic pancreas to differentiate into mature
islet endocrine cells, recapitulating their role in the embryonic
mode of endocrine pancreatic development.96-98 This would tend
to downplay potential roles of bone marrow, spleen and liver
as primary sources of stem cell for adult islet regeneration but
suggest that going several steps back to attempting might not be
entirely farfetched.99
Assuredly, he’d likely be interested in some tantalizing developments suggesting the possibilities of (1) differentiating an
embryonic stem (i.e., pluripotential cells derived from the inner
mass of the blastocyst) through a pancreatic endodermal stage,
which then could be matured into pro-endocrine cells, and
(2) reprogramming of adult pancreatic exocrine cells into b-cells
by inducing the re-expression of several transcription factors.100
In the first case, one such recent attempt has made use of an initial induction factor, activin A and culminated in the maturation
of foregut-like tissue after several month of implantation/maturation in mice made diabetic with streptozotocin. Improved glycemic control was achieved, though C-peptide secretion from
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these cells are not well regulated. In the second case, the transcription factors are NGn3, Pdx1 and Mafa.
Lastly, he’d likely give a critical eye to a recently reported
conditionally transformed (reversibly immortalized) nontumorigenic human b-cell clone (NAKT-15). These reverted
cells display a large complement of insulin granules, hormone
processing enzymes and b-cell transcription factors (e.g., Pdx-1)
as well as impressive increases in insulin and C-peptide secretion in response to 25 mM glucose, and control blood glucose
for up to 30 weeks in combined immunodeficient mice made
diabetic with streptozotocin.101 One might almost here Lacy say
that we’re not there yet, but a little closer.102
Interrupting islet gluco-and lipo-toxicity and prevention of
type 2 DM. In the 1990s the previously vague issue of glucotoxicity, which Lacy and his endocrinology colleague David Kipnis
recognized in the 1960s, started to be more clearly objectified.
While short periods (few hours) of hyperglycemia may be stimulus for β-cell mitosis and neogenesis, prolonged hyperglycemia
has an opposite effect.101 Several lines of experiments revealed
that islets incubated with even twice normal glucose concentration (11 mM) for as little as one week showed increased rates of
insulin release at low (1.7–3 mM) glucose yet failed to increase
their secretion further at elevated (16.7 mM) glucose, despite
having adequate insulin stores and pro-insulin synthesis and
hyperglycemia-induced increases in glucose oxidation.103 β-cells
had “tuned out” to glucose, but why? The situation was clearly
worsened by incubation with 28 mM glucose, where insulin
synthesis was massively downregulated. More recent data suggest that in partially pancreatectomized rats with elevated serum
glucose concentrations, β-cells in remnant islets actually dedifferentiate and lose mRNA coding for most of the proteins in the
cascade for glucose signaling. Surprisingly, they also upregulate
mRNA coding for anti-oxidant and anti-apoptotic processes
(e.g., glutathione peroxidase, superoxide dismutase and catalase), which are normally present at quite low levels, and they
are partially protected against corticosteroid-induced apoptosis.104 In a sense, this may represent a balance state of “don’t
overuse it and don’t rapidly loose it.” Islets need this protection
as hyperglycemia, per se, may cause β-cell damage. Prolonged
exposure to elevated glucose may result, among other features, in
(1) secretion of cytokines, such as IL-1γ that induce nitric oxide
synthetase and the production of nitric oxide, which is toxic to
b-cells, probably by inducing both apoptosis and an inflammatory response; and (2) over-synthesis of pro-insulin to be trafficked through the endoplasmic reticulum (ER) resulting in “ER
stress.”105
With this as a basis, attempts have been made in experimental models to protect β-cells from toxicity and potentially reverse
diabetes.106,107 These include rendering patients truly euglycemic
by insulin therapy (as opposed to glucose control by an oral hypoglycemic agent or a peripheral insulin sensitizer); administration of long-acting analogs of glucagon-like peptide 1 (GLP-1),
which in addition to enhancing glucose-induced insulin release
also appears to stimulate β-cell proliferation and inhibit apoptosis; and/or administration of a natural soluble IL-1 receptor
antagonist, IL-1Ra. Other approaches include administration of
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anti-CD3 antibodies to halt autoimmune destruction and bone
marrow engraftment at first detection of autoimmune DM.108 It
is worth recalling that as the metabolic syndrome (or what we
might call “hypertensive diabesity”) develops in glucotoxic individuals, dyslipidemia and β-cell lipotoxicity also occurs. The
latter combination is what appears to be most injurious to isletsin that saturated fatty acids exert pro-apoptotic effects through
production of ceramide that injures mitochondria while low
density lipoproteins appear to be apoptosis-inducing through
c-Jun N-terminal kinase. However, both glucotoxicity and lipotoxicity, if caught early, might be pharmacologically reversible as
well as epidemiologically preventable.

subtle, is never treacherous.” This spirit has been transmitted to
his long term scientific partner David Scharp and former postdoc Camillo Ricordi who vigorously pursue Lacy’s vision of
curative islet transplantation.
Lastly, Paul Lacy conducted his career with intellectual
honesty, openness and generosity of spirit to colleagues with
diverse interests in islet biology and immunology as well as to
generation of medical student, whom he taught and inspired at
Washington University. While studying the sometimes illusive
islet, he personified an ethos of “no man is an island entire of
himself.” That personal legacy may be as memorable as his scientific one.

Epilogue
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